IMP321 + inactivated influenza vaccine

IMP321 + inactivated influenza vaccine is an experimental **combination therapy** designed to enhance immune responses to the influenza vaccine, especially in populations with impaired or suboptimal immunity (e.g., cancer patients, elderly). **IMP321** is a soluble LAG-3Ig fusion protein (also known as eftilagimod alpha), originally developed as an immunomodulator. It acts as an immune adjuvant, enhancing the activation of antigen-presenting cells through MHC Class II binding, with the goal of boosting the T cell response elicited by the co-administered **inactivated influenza vaccine**. The inactivated influenza vaccine provides antigenic stimulation through inactivated viral particles, aiming to confer protection against influenza A and B viruses. This combination has been investigated in clinical trials as an adjuvanted vaccine approach, primarily in oncology or immunocompromised patient settings.

Other names

LAG-3Ig fusion protein + inactivated influenza vaccineIMP321 + IIV